{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:52:54Z","timestamp":1791478374243,"version":"4.3.4"},"reference-count":57,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020481","name":"Shahid Beheshti University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020481","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology, Transfusion and Cell Therapy"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.htct.2026.106352","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T23:38:44Z","timestamp":1777937924000},"page":"106352","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Harnessing the power of natural killer cells in Lymphoma immunotherapy: Overcoming challenges and enhancing treatment options"],"prefix":"10.1016","volume":"48","author":[{"given":"Elham","family":"Roshandel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam Vahdat","family":"Lasemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2442-0635","authenticated-orcid":false,"given":"Maryam","family":"Mehravar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Salimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Majidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Mohammadali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamide Rahmani","family":"Seraji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbas","family":"Hajifathali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.htct.2026.106352_bib0001","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.htct.2026.106352_bib0002","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJMra2027612","article-title":"Diffuse large B-cell lymphoma. Longo DL, editor","volume":"384","author":"Sehn","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.htct.2026.106352_bib0003","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.canlet.2021.07.032","article-title":"Natural killer cells in cancer and cancer immunotherapy","volume":"520","author":"Raskov","year":"2021","journal-title":"Cancer Lett"},{"key":"10.1016\/j.htct.2026.106352_bib0004","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00275","article-title":"Unleashing natural killer cells in the tumor microenvironment-the next generation of immunotherapy?","volume":"11","author":"Ben-Shmuel","year":"2020","journal-title":"Front Immunol"},{"issue":"FEB","key":"10.1016\/j.htct.2026.106352_bib0005","article-title":"Acquired natural killer cell dysfunction in the tumor microenvironment of classic Hodgkin Lymphoma","volume":"9","author":"Chiu","year":"2018","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.htct.2026.106352_bib0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-022-02579-9","article-title":"Insights into the tumor microenvironment of B cell lymphoma","volume":"41","author":"Ng","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.htct.2026.106352_bib0007","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/nrc.2016.73","article-title":"The biology and function of fibroblasts in cancer","volume":"16","author":"Kalluri","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.htct.2026.106352_bib0008","doi-asserted-by":"crossref","DOI":"10.1177\/20503121211069012","article-title":"Tumor promoting roles of IL-10, TGF-\u03b2, IL-4, and IL-35: its implications in cancer immunotherapy","volume":"10","author":"Mirlekar","year":"2022","journal-title":"SAGE open Med"},{"issue":"5","key":"10.1016\/j.htct.2026.106352_bib0009","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41423-019-0206-4","article-title":"Human NK cells: surface receptors, inhibitory checkpoints, and translational applications","volume":"16","author":"Sivori","year":"2019","journal-title":"Cell Mol Immunol"},{"issue":"JUN","key":"10.1016\/j.htct.2026.106352_bib0010","doi-asserted-by":"crossref","first-page":"760","DOI":"10.3389\/fimmu.2017.00760","article-title":"NK cell exhaustion","volume":"8","author":"Bi","year":"2017","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.htct.2026.106352_bib0011","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1365-2567.2006.02321.x","article-title":"Mechanisms of immune suppression by interleukin-10 and transforming growth factor-\u03b2: the role of T regulatory cells","volume":"117","author":"Taylor","year":"2006","journal-title":"Immunology"},{"key":"10.1016\/j.htct.2026.106352_bib0012","first-page":"11","article-title":"Inhibitory receptors and checkpoints in Human NK cells, implications for the immunotherapy of cancer","author":"Sivori","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.htct.2026.106352_bib0013","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.633205","article-title":"Natural killer cell interactions with myeloid derived suppressor cells in the tumor microenvironment and implications for cancer immunotherapy","volume":"12","author":"Zalfa","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.htct.2026.106352_bib0014","first-page":"11","article-title":"Cancer-associated fibroblasts: the chief architect in the tumor microenvironment","author":"Sarkar","year":"2023","journal-title":"Front Cell Dev Biol"},{"issue":"NOV","key":"10.1016\/j.htct.2026.106352_bib0015","article-title":"Tumor microenvironment-induced immunometabolic reprogramming of natural killer cells","volume":"9","author":"Chambers","year":"2018","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.htct.2026.106352_bib0016","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-019-1091-2","article-title":"Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4","volume":"18","author":"Qin","year":"2019","journal-title":"Mol Cancer"},{"issue":"3","key":"10.1016\/j.htct.2026.106352_bib0017","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3390\/ph15030335","article-title":"Revolutionization in cancer therapeutics via targeting major immune checkpoints PD-1, PD-L1 and CTLA-4","volume":"15","author":"Pandey","year":"2022","journal-title":"Pharmaceuticals."},{"issue":"4","key":"10.1016\/j.htct.2026.106352_bib0018","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2217\/epi-2022-0454","article-title":"Natural killer cell epigenetic reprogramming in tumors and potential for cancer immunotherapy","volume":"15","author":"Hojjatipour","year":"2023","journal-title":"Epigenomics"},{"issue":"2","key":"10.1016\/j.htct.2026.106352_bib0019","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/nrclinonc.2010.189","article-title":"Beyond chemotherapy: new agents for targeted treatment of lymphoma","volume":"8","author":"Younes","year":"2011","journal-title":"Nature Reviews Clinical Oncology"},{"key":"10.1016\/j.htct.2026.106352_bib0020","doi-asserted-by":"crossref","DOI":"10.1080\/14728222.2019.1580693","article-title":"The NKG2D axis: an emerging target in cancer immunotherapy","author":"Lazarova","year":"2019","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.htct.2026.106352_bib0021","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.coi.2018.02.004","article-title":"NKG2D and its ligands in cancer","volume":"51","author":"Dhar","year":"2018","journal-title":"Curr Opin Immunol"},{"issue":"3","key":"10.1016\/j.htct.2026.106352_bib0022","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1365-2249.2008.03708.x","article-title":"Differential effects of ifosfamide on dendritic cell-mediated stimulation of T cell interleukin-2 production, natural killer cell cytotoxicity and interferon-\u03b3 production","volume":"153","author":"Kuppner","year":"2008","journal-title":"Clin Exp Immunol"},{"issue":"10","key":"10.1016\/j.htct.2026.106352_bib0023","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13102500","article-title":"Harnessing CD16-mediated NK cell functions to enhance therapeutic efficacy of tumor-targeting mAbs","volume":"13","author":"Capuano","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.htct.2026.106352_bib0024","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/bjh.15797","article-title":"Combination lenalidomide-rituximab immunotherapy activates anti-tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma","volume":"185","author":"Chiu","year":"2019","journal-title":"Br J Haematol"},{"issue":"14","key":"10.1016\/j.htct.2026.106352_bib0025","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.1158\/1078-0432.CCR-07-4405","article-title":"lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells","volume":"14","author":"Wu","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.htct.2026.106352_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101779","article-title":"The iR2 regimen (ibrutinib plus lenalidomide and rituximab) for relapsed\/refractory DLBCL: a multicentre, non-randomised, open-label phase 2 study","volume":"56","author":"Ramchandren","year":"2023","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.htct.2026.106352_bib0027","doi-asserted-by":"crossref","DOI":"10.5772\/intechopen.103705","article-title":"Drugs and drug candidates for the treatment of lymphoma","author":"Acikalin Coskun","year":"2022","journal-title":"Lymphoma"},{"issue":"2","key":"10.1016\/j.htct.2026.106352_bib0028","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/vaccines9020138","article-title":"Targeting innate immunity in cancer therapy","volume":"9","author":"Rameshbabu","year":"2021","journal-title":"Vaccines"},{"issue":"22","key":"10.1016\/j.htct.2026.106352_bib0029","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.4140.4140","article-title":"Ibrutinib potentiated NK cell-mediated cytotoxicity in mouse models of B-cell lymphomas","volume":"128","author":"Kuo","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.htct.2026.106352_bib0030","first-page":"11","article-title":"Selinexor enhances NK cell activation against malignant B cells via downregulation of HLA-E","author":"Fisher","year":"2021","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.htct.2026.106352_bib0031","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-022-01382-5","article-title":"Natural killer cells in clinical development as non-engineered, engineered, and combination therapies","volume":"15","author":"Lamers-Kok","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"3","key":"10.1016\/j.htct.2026.106352_bib0032","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jcyt.2014.09.007","article-title":"Challenges of cancer therapy with natural killer cells","volume":"17","author":"Klingemann","year":"2015","journal-title":"Cytotherapy"},{"issue":"25","key":"10.1016\/j.htct.2026.106352_bib0033","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.1182\/blood-2013-10-532531","article-title":"Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein","volume":"123","author":"Bachanova","year":"2014","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.htct.2026.106352_bib0034","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.3390\/cancers13164129","article-title":"NK cell therapy: a rising star in cancer treatment","volume":"13","author":"Du","year":"2021","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.htct.2026.106352_bib0035","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/s41423-024-01207-0","article-title":"CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors","volume":"21","author":"Peng","year":"2024","journal-title":"Cell Mol Immunol"},{"issue":"4","key":"10.1016\/j.htct.2026.106352_bib0036","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41423-024-01145-x","article-title":"Development of NK cell-based cancer immunotherapies through receptor engineering","volume":"21","author":"Page","year":"2024","journal-title":"Cell Mol Immunol"},{"issue":"6","key":"10.1016\/j.htct.2026.106352_bib0037","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.htct.2026.106352_bib0038","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","article-title":"Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1\/2 trial","volume":"30","author":"Marin","year":"2024","journal-title":"Nat Med"},{"issue":"10473","key":"10.1016\/j.htct.2026.106352_bib0039","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0140-6736(24)02462-0","article-title":"Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial","volume":"405","author":"Ghobadi","year":"2025","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.htct.2026.106352_bib0040","unstructured":"Nkarta Inc. Nkarta announces updated clinical data on anti-CD19 allogeneic CAR-NK cell therapy NKX019 for patients with relapsed or refractory non-hodgkin lymphoma. Nkarta; 2022 Dec 5. Available from: https:\/\/ir.nkartatx.com\/news-releases\/news-release-details\/nkarta-announces-updated-clinical-data-anti-cd19-allogeneic-car\/. Accessed 2026 Apr 29."},{"key":"10.1016\/j.htct.2026.106352_bib0041","series-title":"Adult patients with relapsed\/refractory (R\/R) B-Cell non-hodgkin lymphoma (NHL)","article-title":"Efficacy and safety of TAK-007, cord blood-derived CD19 CAR-NK cells","author":"Darrah","year":"2024"},{"issue":"2","key":"10.1016\/j.htct.2026.106352_bib0042","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3390\/cells13020146","article-title":"Allogeneic CAR-T therapy technologies: has the promise been met?","volume":"13","author":"Lonez","year":"2024","journal-title":"Cells"},{"issue":"26","key":"10.1016\/j.htct.2026.106352_bib0043","doi-asserted-by":"crossref","first-page":"4024","DOI":"10.1182\/blood-2014-12-614636","article-title":"A phase 1 study of the bispecific anti-CD30\/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma","volume":"125","author":"Rothe","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.htct.2026.106352_bib0044","unstructured":"National Library of Medicine (US). Phase II Study to Assess AFM13 in Patients With R\/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides (NCT04101331). ClinicalTrials.gov. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04101331"},{"key":"10.1016\/j.htct.2026.106352_bib0045","unstructured":"Affimed says 86% of patients responded to lymphoma therapy in mid-stage trial. 2024 Jun 12. Available from: https:\/\/seekingalpha.com\/news\/4115178-affimed-stock-gains-data-lymphoma-drug\/. Accessed Apr 29, 2026."},{"issue":"13","key":"10.1016\/j.htct.2026.106352_bib0046","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1158\/1078-0432.CCR-21-0164","article-title":"Combining AFM13, a bispecific CD30\/CD16 antibody, with cytokine-activated blood and cord blood\u2013derived NK cells facilitates CAR-like responses against CD30+ malignancies","volume":"27","author":"Kerbauy","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"Supplement 1","key":"10.1016\/j.htct.2026.106352_bib0047","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-172980","article-title":"Innate cell engager (ICE\u00ae) AFM13 combined with preactivated and expanded (P+E) cord blood (CB)-derived natural killer (NK) cells for patients with refractory CD30-positive lymphomas: final results","volume":"142","author":"Nieto","year":"2023","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.htct.2026.106352_bib0050","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s00262-020-02532-9","article-title":"Current progress in NK cell biology and NK cell-based cancer immunotherapy","volume":"69","author":"Tarazona","year":"2020","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"10.1016\/j.htct.2026.106352_bib0051","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/imr.13031","article-title":"Epigenetic regulation of natural killer cell memory","volume":"305","author":"Lau","year":"2021","journal-title":"Immunol Rev"},{"issue":"1","key":"10.1016\/j.htct.2026.106352_bib0052","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/imr.12947","article-title":"Transcriptional and epigenetic regulation of memory NK cell responses","volume":"300","author":"Beaulieu","year":"2021","journal-title":"Immunol Rev"},{"issue":"13","key":"10.1016\/j.htct.2026.106352_bib0053","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1084\/jem.20120944","article-title":"Sustained effector function of IL-12\/15\/18-preactivated NK cells against established tumors","volume":"209","author":"Ni","year":"2012","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.htct.2026.106352_bib0054","article-title":"Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity","volume":"2011","author":"Sondel","year":"2011","journal-title":"Biomed Res Int"},{"issue":"5","key":"10.1016\/j.htct.2026.106352_bib0055","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41571-019-0182-8","article-title":"The NKG2A immune checkpoint \u2014 A new direction in cancer immunotherapy","volume":"16","author":"Creelan","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"10.1016\/j.htct.2026.106352_bib0056","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1158\/1078-0432.CCR-15-1419","article-title":"The IL-15-based ALT-803 complex enhances Fc\u03b3RIIIa-triggered NK cell responses and in vivo clearance of B cell lymphomas","volume":"22","author":"Rosario","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.htct.2026.106352_bib0057","article-title":"Cytokines induced memory-like NK cells engineered to express CD19 CAR exhibit enhanced responses against B cell malignancies","volume":"14","author":"He","year":"2023","journal-title":"Front Immunol"},{"issue":"705","key":"10.1016\/j.htct.2026.106352_bib0058","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.ade3341","article-title":"Nicotinamide enhances natural killer cell function and yields remissions in patients with non-Hodgkin lymphoma","volume":"15","author":"Cichocki","year":"2023","journal-title":"Sci Transl Med"},{"issue":"7","key":"10.1016\/j.htct.2026.106352_bib0059","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.jcyt.2020.02.004","article-title":"Artificial feeder cells expressing ligands for killer cell immunoglobulin-like receptors and CD94\/NKG2A for expansion of functional primary natural killer cells with tolerance to self","volume":"22","author":"Michen","year":"2020","journal-title":"Cytotherapy"}],"container-title":["Hematology, Transfusion and Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2531137926000994?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2531137926000994?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:05:52Z","timestamp":1791475552000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2531137926000994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":57,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2531137926000994"],"URL":"https:\/\/doi.org\/10.1016\/j.htct.2026.106352","relation":{},"ISSN":["2531-1379"],"issn-type":[{"value":"2531-1379","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Harnessing the power of natural killer cells in Lymphoma immunotherapy: Overcoming challenges and enhancing treatment options","name":"articletitle","label":"Article Title"},{"value":"Hematology, Transfusion and Cell Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.htct.2026.106352","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Espa\u00f1a, S.L.U. on behalf of Associa\u00e7\u00e3o Brasileira de Hematologia, Hemoterapia e Terapia Celular.","name":"copyright","label":"Copyright"}],"article-number":"106352"}}